Community/Retail

Rite Aid Corporation has announced that it has entered into an asset purchase agreement with Walgreens Boots Alliance whereby Walgreens will acquire 2,186 stores, related distribution assets, and inventory from Rite Aid for an all-cash purchase price of $5.175 billion, on a cash-free, debt-free basis.

Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, has achieved Specialty Pharmacy accreditation from URAC, the healthcare industry’s leading certification and accreditation organization that evaluates quality standards.

The 4th of July is a great time to celebrate with family and friends.

Part of the FDA's actions focuses on expediting review of generic applications.

Finding ways to triage patients and identify those with the greatest need is important.

Pharmacists working in eastern North Carolina counties have developed a program to improve immunization among low income, uninsured patients.

Walgreens and LabCorp have announced a collaboration through which LabCorp will develop and operate patient service centers within select Walgreens stores.

Summer has begun, and people must be more cautious of their surroundings when going outdoors.

Despite recent concerns about proton pump inhibitor (PPI) safety, a recently-published study found no evidence that PPI use contributes to a higher risk of dementia or Alzheimer’s disease in older adults.

As part of its comprehensive national plan to combat drug abuse, Walgreens has announced that it has made naloxone, a lifesaving opioid antidote, available without a prescription in all of its Michigan pharmacies in accordance with state pharmacy regulations.

National HIV Testing Day, on June 27, promotes awareness of the importance of testing in the prevention and care of HIV infection.

A Staten Island physician was recently charged for his involvement in an oxycodone distribution conspiracy that yielded the diversion of millions of dollars’ worth of pain medication.

A new report on national trends in prescription drug expenditures published in AJHP (American Journal of Health-System Pharmacy) projects a 6 to 8% increase in total drug expenditures in 2017 across all healthcare settings.

The American Pharmacists Association (APhA) Foundation today announced results from the pilot phase of Project IMPACT Immunizations.

To avoid the tax pitfalls of procrastination, here are 4 accounting and tax tips to implement!

Gray market diagnostic OTC medical devices pose substantial health and safety risks to patients.

The role of the pharmacist should be made known to our patients and the community.

The FDA approved betrixaban on June 23 as the first oral agent for the prevention of VTE prophylaxis in hospitalized medically ill adults

The opioid crisis is a major concern worldwide, with overdoses accounting for the number 1 cause of accidental deaths in the United States.

Bevyxxa has been approved based on data from Portola's phase 3 APEX Study.

Levi Smith, PharmD, MS, PhD Candidate at Yale University highlights the path of a drug from target discovery all the way to clinical uses and applications.

Digital Eye Strain (also known as computer vision syndrome) and blue light is not something I imagine is covered in many colleges of pharmacy across the country. It is the physical discomfort that is felt after spending more than two hours in front of a digital device screen. In addition to eyestrain, symptoms of computer vision syndrome can include: headaches, blurred vision, dry eye, neck and shoulder pain. Although the use of any digital device can cause digital eye strain, according to The Vision Council, devices that are most commonly used are: desktop computers, laptop computers, televisions, smartphones, tablets, and video games. In the age of technology, digital eye strain is something that all pharmacists should know about; not only to help patients protect their vision, but to help protect and preserve their own vision.

Sometimes you can work with drug reps to improve care for your patients.

Summer is here, and pharmacists may be considering trying new and exciting activities.

The approval is based on multiple clinical trials, and provides patients with a subcutaneous option for rituximab that shortens the treatment time to 5 to 7 minutes compared with intravenous infusion.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.